Under construction – not a live service
Sign in
Not yet recruitingNo phase

Prognostic Role of High Sensitivity Troponin During Follow up in the Evolution of Acute Myocarditis

Key facts

Who runs it
University Hospital, Grenoble
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
244 people, planned
Started
Jul 2023
Expected to end
Jul 2030
Type of study
Observational
Record updated
18 July 2023

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Male or female patients over 18 years of age
  • Patients hospitalized at Grenoble Alpes University Hospital and Lyon University Hospital between June 2016 and June 2025
  • Having presented chest pain and ≥1 diagnostic criteria or if no chest pain, presence of ≥2 diagnostic criteria below :; Electrical abnormalities (supra- or sub-ST, T-wave inversion, atrioventricular blocks 1-3 conduction disorders); Elevation of cardiac biomarkers (troponin); Kinetic abnormalities on cardiac ultrasound
  • Associated with ≥2 MRI criteria of tissue abnormality (edema, hyperhemia, myocardial fibrosis)
  • Patient affiliated to a social security scheme or beneficiary of such a scheme
  • No opposition to participation

Who cannot take part

  • Myocarditis secondary to immunotherapy
  • Presence of documented coronary artery disease (coronary angiography or cardiac CT)
  • Infiltrative heart disease (sarcoidosis or cardiac amyloidosis)
  • Severe valve disease
  • Cardiac tumor
  • Absence of documented coronary artery disease (cardiac CT or coronary angiography) or age <30 and low risk of coronary artery disease
  • Presence of cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy)
  • Takotsubo
  • Constrictive or chronic pericarditis
  • Loeffler's endocarditis
  • Non-compaction of the left ventricle
  • Pulmonary embolism
  • Coronary spasm
  • Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code (pregnant women, parturients, nursing mothers; persons deprived of liberty by judicial or administrative decision; protected adults)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to observe if ultra-sensitive troponins (us) measurement between 3 and 6 months after the acute event will be sensitive enough to dispense with all other examinations, particularly cardiac magnetic resonance imaging (MRI), in patients suffering from myocarditis.

Read full original descriptionShow less

The investigators will collect patient events by telephone, once a year for 4 years.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prognostic Role of Troponin Dosed at 3 to 6 Months in the Evolution of Acute Myocarditis
Record updated
18 July 2023